Saturday 17 October 2026 Export SLS’s income statement to Excel — free account

SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $1.0 million. In the quarter to June 2026, EPS grew 28.6% and free cash flow fell 3.52%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

9.98 1.36 −11.99%

Follow SLS

Alert me

Market cap: $2.3B
P/E: 0.0×
Fwd P/E: −10.0×
Dividend yield: —
F-score: 2/9
Altman Z: −16.75
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.10

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 2,290.00

Revenue 10.50

Net Income (32.46)

Free Cash Flow (28.42)

Net Debt (138.44)

Current Ratio 18.83

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (10.00)

P/S ratio 179.81

P/B ratio 13.72

Past 5Y EPS Growth —

This Y EPS Growth 18.00%

Next Y EPS Growth 53.66%

Next Y revenue growth (100.00%)

Next 5Y EPS Growth 50.68%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 94.64%

10-year low 10-year high

P/B against its own 10 years 89.92%

10-year low 10-year high

EV/Sales against its own 10 years 94.64%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	3	14	72	138
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	3	16	75	143

	2023	2024	2025	Q'26
Payables	6	4	3	3
ST’ Debt	—	—	—	—
Other	—	—	—	—
	14	10	7	8

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	18.02%	20.44%	144.46%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’22	1	—	—	—	1
’21	6	2	—	—	8

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(8)	—	—	—
’25	(9)	(7)	(7)	(5)	(28)
’24	(11)	(10)	(8)	(7)	(35)
’23	(12)	(8)	(7)	(5)	(31)
’22	(7)	(6)	(6)	(5)	(24)
’21	(10)	(5)	(6)	(5)	(26)
’20	(7)	(3)	(4)	3	(10)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(8)	—	—	—
’25	(9)	(7)	(7)	(5)	(28)
’24	(11)	(10)	(8)	(7)	(35)
’23	(12)	(10)	(10)	(5)	(37)
’22	(7)	(10)	(6)	(10)	(33)
’21	(10)	(5)	(6)	(5)	(26)
’20	(7)	(3)	(4)	3	(10)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.05)	(0.05)	—	—	—
’25	(0.07)	(0.07)	(0.06)	(0.05)	(0.25)
’24	(0.21)	(0.13)	(0.10)	(0.08)	(0.50)
’23	(0.47)	(0.31)	(0.33)	(0.25)	(1.34)
’22	(1.05)	(0.41)	(0.34)	(0.43)	(2.13)
’21	(0.16)	(0.30)	(0.45)	(0.42)	(1.34)
’20	(0.66)	(0.66)	(0.53)	(0.28)	(2.11)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	2,760.00	390.00	40.00	3.54	1.46	5.20	1.77	0.81	0.50	0.85	Analyst estimates 2026–2028 Powerpack
	High	74,700.00	3,615.00	554.50	89.50	19.38	15.08	7.40	4.13	1.72	3.99
People
People	Employees	14	9	9	5	7	11	17	16	15	13
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.27	0.69	0.06	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	2	8	1	—	—	—
	Gross margin, %	0.00	—	—	—	100.00	97.37	90.00	—	—	—
	EBT	(18)	(24)	(29)	(19)	(17)	(21)	(41)	(37)	(31)	(27)
	EBT margin, %	0.00	0.00	0.00	0.00	(882.84)	(275.47)	(4,130.10)	0.00	0.00	0.00
	Net income	(18)	(24)	(28)	(19)	(17)	(21)	(41)	(37)	(31)	(27)
	Depreciation	0	0	9	3	0	—	—	—	—	—
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.24	0.49	0.05	0.00	0.00	0.00
	Earnings	(933.53)	(522.00)	(157.50)	(10.92)	(2.11)	(1.34)	(2.13)	(1.34)	(0.50)	(0.25)
	Cash flow	(626.98)	(234.81)	(116.11)	(6.89)	(1.31)	(1.68)	(1.23)	(1.13)	(0.58)	(0.26)
	Capex	0.00	0.00	0.00	0.00	0.00	0.00	(0.46)	(0.20)	0.00	0.00
	Free cash flow	(626.98)	(234.81)	(116.11)	(6.89)	(1.31)	(1.68)	(1.69)	(1.33)	(0.58)	(0.26)
	Book value	(264.39)	44.23	20.02	2.38	3.51	1.31	0.25	(0.29)	0.15	0.65
	Shares, m	0	0	0	3	8	15	19	28	61	109
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	0.00	0.00	—	—	—
	P/S	—	—	—	—	6.12	7.24	4.71	—	—	—
	P/B	—	—	—	—	1.66	4.21	10.20	—	—	—
	EV/Sales	—	—	—	—	1.56	5.48	3.11	—	—	—
	EV/FCF	—	—	—	—	(1.13)	(2.48)	(1.15)	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(12)	(11)	(30)	(18)	(10)	(26)	(24)	(31)	(35)	(28)
	Capex	—	—	—	—	—	—	(9)	(5)	0	—
	Free cash flow	(12)	(11)	(30)	(18)	(10)	(26)	(33)	(37)	(35)	(28)
Balance, $m
Balance, $m	Working capital	1	(11)	0	3	25	18	2	(11)	7	68
	Total debt	7	11	—	0	1	1	1	—	—	—
	Net debt	1	(2)	(5)	(7)	(35)	(21)	(17)	(3)	(14)	(72)
	Shareholders’ equity	(5)	2	5	6	28	20	5	(8)	9	71
Returns, %
Returns, %	ROA	(39.93)	(122.31)	(163.56)	(166.75)	(53.74)	(57.24)	(174.94)	(274.94)	(240.78)	(54.95)
	ROIC	0.00	(4,675.12)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(415.24)	1,669.22	(1,127.85)	(493.05)	(98.87)	(85.70)	(327.81)	2,389.76	(4,147.88)	(66.88)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2022 · latest quarter Mar 2022

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ADMA ADMA Biologics Inc	$2.4B	14.8×	9.5×	+1.98% (above 0%: growing)	+21.43% (above 0%: growing)	+19.72% (above 0%: growing)	69.36%	42.16%	Compare
SLS SELLAS Life Sciences Group, Inc.	$2.3B	— (loss-making)	— (loss-making)	−57.10% (below 0%: shrinking)	n/m	−3.52% (below 0%: shrinking)	0.00%	0.00%
CLDX Celldex Therapeutics, Inc.	$2.3B	— (loss-making)	— (loss-making)	−96.83% (below 0%: shrinking)	n/m	−35.45% (below 0%: shrinking)	100.00%	(366,468.18%)	Compare
AUPH Aurinia Pharmaceuticals Inc	$2.2B	6.9×	16.5×	+18.87% (above 0%: growing)	+81.25% (above 0%: growing)	+19.08% (above 0%: growing)	92.12%	48.19%	Compare
HRMY Harmony Biosciences Holdings, Inc.	$2.2B	12.2×	9.4×	+30.32% (above 0%: growing)	+88.41% (above 0%: growing)	+16.53% (above 0%: growing)	75.81%	34.18%	Compare
RXRX Recursion Pharmaceuticals, Inc.	$2.2B	— (loss-making)	— (loss-making)	−60.10% (below 0%: shrinking)	n/m	−32.03% (below 0%: shrinking)	(49.82%)	(1,759.69%)	Compare
VRDN Viridian Therapeutics, Inc.	$2.2B	— (loss-making)	— (loss-making)	+278.67% (above 0%: growing)	n/m	−41.39% (below 0%: shrinking)	100.00%	(44,460.56%)	Compare
IRON Disc Medicine, Inc.	$2.2B	— (loss-making)	—	—	n/m	+7.83% (above 0%: growing)	0.00%	0.00%	Compare
FTRE Fortrea Holdings Inc.	$2.2B	— (loss-making)	— (loss-making)	−4.52% (below 0%: shrinking)	n/m	+53.15% (above 0%: growing)	20.52%	2.18%	Compare
Median of peers	$2.2B	12.2×	9.5×	+1.98%	+81.25%	+12.18%	72.59%	1.09%

All 614 Biotechnology stocks →

SELLAS Life Sciences Group, Inc. (SLS) key facts

SELLAS Life Sciences Group, Inc. (SLS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
SELLAS Life Sciences Group, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $1.0 million.
As of October 16, 2026, SLS traded at $9.98, a market capitalization of $2.3 billion.
Return on equity was −66.9% and debt-to-equity 0.00.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −16.75 (distress zone) for fiscal 2022.

Source: company filings (standardised) and stockrow calculations.